Accessibility navigation


Mass spectrometry in clinical proteomics - from the present to the future

Palmblad, M., Tiss, A. and Cramer, R. (2009) Mass spectrometry in clinical proteomics - from the present to the future. Proteomics Clinical Applications, 3 (1). pp. 6-17. ISSN 1862-8346

Full text not archived in this repository.

To link to this article DOI: 10.1002/prca.200800090

Abstract/Summary

MS is an important analytical tool in clinical proteomics, primarily in the disease-specific discovery identification and characterisation of proteomic biomarkers and patterns. MS-based proteomics is increasingly used in clinical validation and diagnostic method development. The latter departs from the typical application of MS-based proteomics by exchanging some of the high performance of analysis for the throughput, robustness and simplicity required for clinical diagnostics. Although conventional MS-based proteomics has become an important field in clinical applications, some of the most recent MS technologies have not yet been extensively applied in clinical proteomics. in this review, we will describe the current state of MS in clinical proteomics and look to the future of this field.

Item Type:Article
Refereed:Yes
Divisions:Faculty of Life Sciences > School of Chemistry, Food and Pharmacy > Department of Chemistry
ID Code:11548
Uncontrolled Keywords:Clinical proteomics, Diagnostics, Mass spectrometry, Profiling, Screening , LASER-DESORPTION/IONIZATION-TIME, NIPPLE ASPIRATE FLUID, SELDI-TOF-MS, PROTEIN IDENTIFICATION TECHNOLOGY, DIFFERENCE GEL-ELECTROPHORESIS, MALIGNANT MAMMOGRAPHIC LESIONS, SERUM PEPTIDOME PATTERNS, HUMAN PLASMA PROTEOME, BREAST-CANCER, OVARIAN-CANCER

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation